重组人血管内皮抑素治疗晚期NSCLC的价值

The Values of Recombinant Human Endostatin in the Treatment of Advanced NSCLC

目的探讨重组人血管内皮抑素治疗晚期非小细胞肺癌(NSCLC)的价值。方法采用回顾性研究方法,选择肿瘤科诊治的晚期NSCLC患者88例,根据治疗方法的不同分为实验组48例与对照组40例,对照组采用NP方案化疗,实验组在对照组治疗的基础上给予重组人血管内皮抑素治疗,两组都治疗观察3个周期,记录与随访预后疗效。结果实验组与对照组治疗总有效率分别为68. 8%和50. 0%,实验组高于对照组(P <0. 05)。两组治疗期间的不良反应主要为消化道反应、血液系统反应、肝肾反应、皮肤反应等,多为Ⅰ~Ⅱ级,对比差异无统计学意义(P> 0. 05)。两组治疗后血清E-cadherin水平低于治疗前,实验组低于对照组,对比差异都有统计学意义(P <0. 05)。随访至2018年8月,实验组的总生存期与无进展生存时间显著多于对照组(P <0. 05)。结论重组人血管内皮抑素治疗晚期NSCLC能抑制E-cadherin的表达,不会增加不良反应的发生,从而提高治疗效果,延长患者的生存期。

Objective To investigate the values of recombinant human endostatin in the treatment of advanced non-small cell lung cancer( NSCLC). Methods Used a retrospective study,88 patients with advanced NSCLC were selected and were divided into the 48 patients in the experimental group and 40 patients in the control group according to the different treatment methods. The control group were given NP regimen chemotherapy,and the experimental group were given recombinant human endostatin on the basis of the control group. The 2 groups were treated for 3 cycles,and the prognosis were recorded and followed up. Results The total effective rates of the experimental group and the control group were 68. 8% and 50. 0%,respectively,and the experimental group were higher than the control group( P < 0. 05). The adverse reactions during the 2 groups were mainly digestive tract reaction,blood system reaction,liver and kidney reaction,skin reaction,etc.,mostly were 1-2 grades,the difference between the 2 groups were not statistically significant( P > 0. 05). The serum E-cadherin levels in the 2 groups were lower than those before treatment,and the experimental group were lower than the control group,the difference were statistically significant( P <0. 05). Followed-up to August 2018,the total survival time and progression-free survival time of the experimental group were significantly higher than those of the control group( P < 0. 05). Conclusion The recombinant human endostatin can inhibit the expression of E-cadherin in advanced NSCLC without increase the incidence of adverse reactions,thereby improve the therapeutic effect and prolong the survival of patients.